SFMBT2 and breast carcinoma: We proceeded to assess the association between the expression of circRNA-SFMBT2 and clinicopathological variables by categorizing all patients with ER+ breast cancer into high- and low-expression groups based on the average value of circRNA-SFMBT2 expression determined by PCR as the cutoff (Table 1).